Since 2015, large-scale cardiovascular outcome trials (CVOTs) have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce the risk of major adverse cardiovascular events, cardiovascular mortality, and heart failure hospitalization in patients with T2DM and established cardiovascular disease or high-risk profiles
doi: 10.1016/j.jaad.2021.01.073
higher-dose oral therapy (1,0002,000 micrograms daily) may be considered as an alternative to injections in selected cases with adequate absorption For those taking supplements , consider these safety principles: Use supplements only when clinically indicated (confirmed deficiency or high-risk groups such as vegans, elderly, or those with malabsorption) In the UK, hydroxocobalamin is the preferred injectable form Avoid mega-doses without medical supervision
SeekPeptides has reviewed many of these alternatives in depth
Is L-carnitine approved by the FDA
Patients with inflammatory bowel disease are at an increased risk of Parkinsons Disease: a south Korean nationwide population-based study
